Tiotropium add-on therapy improves lung function in children and adolescents with moderate and severe symptomatic asthma, independent of markers of allergic status

Purpose: Tiotropium add-on therapy has demonstrated efficacy and safety in 6–17 year-old patients with moderate and severe symptomatic asthma despite inhaled corticosteroid (ICS) treatment ± other controllers. Since allergic asthma is the most common phenotype, we assessed whether the allergic status impacts lung function improvements with tiotropium add-on therapy in these patients. Methods: Analyses involved four Phase III, randomized, double-blind, placebo-controlled, parallel-group trials in patients aged 6–11 years and 12–17 years. Two were 12-week …